CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2018 Miami Lung Cancer Conference
Oncology Conference Multimedia
View more videos >>
Dr. Lopes Discusses the Importance of Addressing Financial Toxicity in Lung Cancer
Dr. Wakelee on First-Line Therapy for EGFR-Mutant Lung Cancer
Dr. Naidoo Discusses the Management of Immune-Related Adverse Events in Lung Cancer
Oncology Conference Articles
Naidoo Discusses Advances in the Management of Immunotherapy-Related AEs
Jarushka Naidoo, MBBCh, discusses some of the most commonly seen immune-related adverse events in patients with lung cancer and how to manage them.
Novel Agents Emerging for Lesser-Known Targets in NSCLC
are all less common molecular targets found in non–small cell lung cancer, but emerging therapeutic strategies are being explored to attack these abnormalities.
BRAF V600E Testing Necessary in NSCLC, but Experts Unsure of Optimal Setting With BRAF/MEK Combo
Upfront testing for
V600E mutations is necessary for patients with non–small cell lung cancer, but if results are positive, physicians are unsure when to administer BRAF/MEK combination therapy—and they must be prepared to manage the associated adverse events.
Wakelee Discusses Debate Surrounding Osimertinib in Frontline EGFR-Mutant Lung Cancer
Heather Wakelee, MD, discusses the rapidly changing landscape of frontline EGFR tyrosine kinase inhibitors in non–small cell lung cancer.
Immunotherapy Making Headway in SCLC and Mesothelioma
Immune-based therapies continue to show promising signals for patients with small cell lung cancer and mesothelioma, but better predictive biomarkers are needed to determine who is most likely to benefit.
Studies Highlight Rationale for Immunotherapy in Early-Stage and Locally Advanced NSCLC
With durvalumab (Imfinzi) being hailed as a potentially practice changing therapy in locally advanced non–small cell lung cancer, ongoing studies are seeking to determine the efficacy of immunotherapy in earlier stages of disease.
Expert Addresses Global Disparities in Lung Cancer, Efforts to Bridge the Gap
Gilberto Lopes, MD, discusses the global disparities occurring in lung cancer care and some of the steps that are being taken to better serve patients with the available and emerging therapeutic approaches.
Brahmer Highlights Latest on Immunotherapy and Other Lung Cancer Advances
Julie R. Brahmer, MD, discusses first-line immunotherapy, targeted therapies for molecularly driven tumors, and recently released guidelines for the treatment of patients with lung cancer.
Goldberg Gives Expert Insight on EGFR-TKI Resistant NSCLC
Sarah B. Goldberg, MD, discusses testing for and treating resistance to EGFR TKI therapy in non-small cell lung cancer.
FDA Approvals in Myeloma and aTTP, Priority Review Designations in RCC and HNSCC, and More
Novel Agents Spark New Approaches for Triple-Negative Breast Cancer
Hereditary Prostate Cancer—What Urologists Should Know
FDA Grants Pembrolizumab/Axitinib Combo Priority Review for Frontline RCC
Targeting BCL-2 in Hematologic Malignancies
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.